Research programme: cancer therapeutics - Hutchison MediPharma

Drug Profile

Research programme: cancer therapeutics - Hutchison MediPharma

Alternative Names: HMPL 453

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 14 Nov 2016 Hutchison Medipharma plans a first-time-in-human phase I trial for Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Australia (PO, Tablet) (NCT02966171)
  • 02 Aug 2016 Hutchison MediPharma files an IND application with the China FDA for Solid tumours
  • 24 Sep 2015 Preclinical trials in Solid tumours in World (PO) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top